Literature DB >> 3812287

Isolated replacement of a prosthesis or a bioprosthesis in the mitral valve position.

M J Antunes, M P Magalhäes.   

Abstract

The operative results of 249 mitral valvular reoperations performed in 215 patients from 1974 through 1986 were reviewed to identify groups at greater risk. Two to 4 reoperations were performed in 28 patients. The mean interval between the first and second valve procedures was 47 +/- 40 months. The most common indications for reoperation were degeneration of bioprostheses (44%) and thrombosis of mechanical prostheses (26%). Thirty patients (12%) died. This rate was significantly higher (p less than 0.02) than that for primary valve procedures performed during the same period. The mortality rate for elective reoperations was 7%. Mortality rates were higher among patients with prosthetic valve endocarditis (6 of 17 cases, 35%), in those undergoing operation on an emergency basis (19 of 82, 23%) and when tricuspid valve replacement or anuloplasty was also performed (9 of 38, 24%) (p less than 0.02). No significant correlation was found between mortality rates and the age or sex of the patients and the types of prosthesis used originally.

Entities:  

Mesh:

Year:  1987        PMID: 3812287     DOI: 10.1016/0002-9149(87)90811-3

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  2 in total

1.  Reoperative Mitral Surgery Versus Transcatheter Mitral Valve Replacement: A Systematic Review.

Authors:  Aditya Sengupta; Farhang Yazdchi; Sophia L Alexis; Edward Percy; Akash Premkumar; Sameer Hirji; Vinayak N Bapat; Deepak L Bhatt; Tsuyoshi Kaneko; Gilbert H L Tang
Journal:  J Am Heart Assoc       Date:  2021-03-09       Impact factor: 5.501

2.  Redo surgery risk in patients with cardiac prosthetic valve dysfunction.

Authors:  Marek Maciejewski; Katarzyna Piestrzeniewicz; Agata Bielecka-Dąbrowa; Monika Piechowiak; Ryszard Jaszewski
Journal:  Arch Med Sci       Date:  2011-05-17       Impact factor: 3.318

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.